Intellia Therapeutics is a genome editing company focused on developing therapeutics utilizing a biological tool known as Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9). This is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. Co. utilizes its CRISPR/Cas9 platform across two areas: in vivo and ex vivo therapies. Co.'s in vivo candidate, NTLA-2001 for the treatment of transthyretin amyloidosis is the delivered CRISPR/Cas9-based therapy to enter clinical evaluation. Co.'s ex vivo applications to address immuno-oncology and autoimmune diseases. We show 26 historical shares outstanding datapoints in our coverage of NTLA's shares outstanding history.
Understanding the changing numbers of NTLA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NTLA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NTLA by allowing them to research NTLA shares outstanding history
as well as any other stock in our coverage universe. |
Free NTLA Email Alerts:
Video: Shares Outstanding Importance
